Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
20 participants
OBSERVATIONAL
2025-09-02
2026-09-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms);
2. To identify potential molecular markers predictive of disease progression;
3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optical Coherence Tomography Imaging in Systemic Sclerosis
NCT04532151
Development and Prevention of Severe Heart Disease in Systemic Sclerosis
NCT01829126
Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
NCT05273138
Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre
NCT04265144
Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis
NCT07015060
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities
* At least one first-degree relative with systemic scleroderma meeting the same criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - France
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9820
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.